The US pharmaceutical company, Merck, has announced that two of its trials (KEYNOTE-183 and KEYNOTE-185) investigating pembrolizumab (Keytruda®) treatment combinations for myeloma patients have paused new patient enrollment. Based on recommendations by the external data monitoring committee, additional information is being collected to better understand the increased reports of deaths in the pembrolizumab groups. Patients currently participating in the trials are unaffected and will continue to receive treatment. Other pembrolizumab trials are also unchanged.


Read article